Rice Hall James & Associates’s Albany Molecular Research Inc AMRI Stock Holding History

Rice Hall James & Associates’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,234,440	Closed	-$17.3M	–	318
2017 Q1	$17.3M	Sell	1,234,440 -27,494	-2%	-$450K	0.84%	51
2016 Q4	$23.7M	Sell	1,261,934 -27,687	-2%	-$471K	1.19%	13
2016 Q3	$21.3M	Sell	1,289,621 -7,591	-0.6%	-$112K	1.11%	17
2016 Q2	$17.4M	Sell	1,297,212 -21,019	-2%	-$307K	1%	28
2016 Q1	$20.2M	Sell	1,318,231 -2,224	-0.2%	-$34.9K	1.16%	20
2015 Q4	$26.2M	Buy	1,320,455 +161,609	+14%	+$3.07M	1.5%	4
2015 Q3	$20.2M	Buy	1,158,846 +87	+0%	+$1.77K	1.31%	16
2015 Q2	$23.4M	Buy	1,158,759 +7,958	+0.7%	+$154K	1.35%	11
2015 Q1	$20.3M	Buy	+1,150,801	New	+$19.6M	1.17%	15

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Rice Hall James & Associates's AMRI Position: Q2 2017 in Review

Rice Hall James & Associates sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 1,234,440 shares — an estimated $17.3M sold.

Rice Hall James & Associates first reported a position in AMRI in Q1 2015 and held it in 9 quarters. The position peaked at $26.2M in Q4 2015. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Rice Hall James & Associates reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Rice Hall James & Associates sold 1,234,440 Albany Molecular Research Inc shares in Q2 2017, an estimated $17.3M.
Rice Hall James & Associates first reported a position in Albany Molecular Research Inc in Q1 2015 and held it in 9 quarters.
Rice Hall James & Associates's Albany Molecular Research Inc position peaked at $26.2M in Q4 2015.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Rice Hall James & Associates's 13F filing for Q2 2017, filed 2 Aug 2017.